Defining and tracing subtypes of patient-derived xenograft models in pancreatic ductal adenocarcinoma  

作　　者：Sangyeop Hyun Youngmin Han Jae Yun Moon Young-Ah Suh Won-Gun Yun Wooil Kwon Jong-Eun Lee Daeun Kim Ja-Lok Ku Jin-Young Jang Daechan Park 

机构地区：[1]Department of Molecular Science and Technology,Ajou University,Suwon,Republic of Korea [2]Department of Surgery and Cancer Research Institute,Seoul National University College of Medicine,Seoul,Republic of Korea [3]Molecular Science and Technology Research Center,Ajou University,Suwon,Republic of Korea [4]DNA Link Inc.,Seoul,Republic of Korea [5]Korean Cell Line Bank,Laboratory of Cell Biology,Cancer Research Institute,Seoul National University College of Medicine,Seoul,Republic of Korea

出　　处：《Cancer Communications》2024年第8期915-920,共6页癌症通讯（英文）

基　　金：supported by Global-Learning&Academic research institution for Master’s PhD students,Postdocs(G-LAMP)Program through the National Research Foundation of Korea(NRF)funded by the Ministry of Education(RS-2023-00285390 to Daechan Park);the NRF grant funded by the Ministry of Science and ICT(RS-2024-00341899 to Daechan 2022R1A2C2011122 to Jin-Young Jang);supported by DNA Link,Inc.,and there is no conflict of interest.

摘　　要：Patient-derived xenograft(PDX)models have been used to explore therapeutic opportunities for pancreatic ductal adenocarcinoma(PDAC)[1].Although original tumor characteristics are altered by cancer-stromal interactions in a PDX-specific manner[2],the implications of clonal evolution from PDAC tumors to PDX are largely unknown.

关 键 词：ADENOCARCINOMA DUCTAL XENOGRAFT 

分 类 号：R735.9[医药卫生—肿瘤]